Search Results

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR) (NVL-655-04) MOA: NVL-655 is an ALK TKI, designed for broader coverage of ALK resistance mutations, activity in the CNS, and selectivity over TRKB. Key Eligibility Criteria:…

A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer (OPERA-02) OP-1250-302 MOA: Palazestrant (OP-1250) is an oral complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD) Key Eligibility Criteria: Confirmed ER+ (≥1%) /HER2-negative MBC and one…

INCA033890-303: A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer MOA: INCA33890 is a Fc-silenced, IgG1 bispecific antibody that can simultaneously bind to both PD-1 and TGFβR2. Key Eligibility Criteria: Histologically or cytologically confirmed metastatic colorectal adenocarcinoma not amenable…

A Phase 2/3 Interventional Study Of PF-08634404 In Combination With Chemotherapy In Treatment-Naïve Participants With Locally Advanced Or Metastatic Gastric, Gastroesophageal Junction, Or Esophageal Adenocarcinoma MOA: PF-08634404 is a recombinant anti-PD-1 and anti-VEGF human mAb Key Eligibility Criteria: Histologically or cytologically confirmed gastric, GEJ, or esophageal adenocarcinoma that is locally advanced unresectable or metastatic No…

Kristen has been practicing as a Physician Assistant since 2011. Prior to joining MOH in 2021, she worked in primary care within the community where she was born and raised, developing strong, lasting relationships with her patients and their families. She earned her Bachelor of Science in Biology from Campbell University in North Carolina and…

Michele Cleary is a board-certified Family Nurse Practitioner and Oncology Certified Nurse with more than 30 years of experience in hematology and oncology care. She currently practices as a Nurse Practitioner at Maryland Oncology Hematology, where she provides comprehensive, patient-centered care in the outpatient setting. She attended Charles County Community College, The University of Maryland…